Video

The Cancer Moonshot and Parker Institute for Cancer Immunotherapy

Author(s):

Ramy Ibrahim, M.D.

Ramy Ibrahim, M.D., vice president of Clinical Development at the Parker Institute for Cancer Immunotherapy discusses how the institute's mission aligns with the mission of the Cancer Moonshot.

Ramy Ibrahim, M.D., vice president of Clinical Development at the Parker Institute for Cancer Immunotherapy discusses how the institute's mission aligns with the mission of the Cancer Moonshot.

Both the Moonshot and the Parker Institute for Cancer Immunotherapy recognize that it is crucial to have enough resources to advance cancer sciences. The Parker Institute is working with top scientists and academic centers to reduce obstacles and barriers to immunotherapy research.

Related Videos
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Bald Doctor.
Dr. Anna Arthur is the Director of the Medical Nutrition Science Program, as well as a tenure-track Assistant Professor in the Department of Dietetics and Nutrition at the University of Kansas Medical Center.
Dr. Ritu Salani, the Director of Gynecologic Oncology at the University of California, Los Angeles (UCLA), UCLA Health, and a board-certified gynecologic oncologist.
Image of Dr. Scott Kopetz
Image of Dr. Susumu Hijoka
Image of Dr. Braun.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Michael Bogenschutz
Related Content
Image of man with black hair.
February 3rd 2025

Rybrevant Alone and in Combo With Chemo is Efficacious in HER+ mCRC

Ryan Scott
Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified metastatic colorectal cancer.
Site Logo
May 9th 2019

Speaking Out About Breast Implant-Associated Cancer

Kristie L. Kahl
In this episode of CURE® Talks Cancer, we spoke with an advocate who is raising awareness around the recent controversy surrounding a certain type of breast implant that is causing a rare type of lymphoma.
Image of man with grey hair.
January 16th 2025

An Expert Breaks Down the Meaning of MRD Testing in Cancer Care

Ryan Scott
Dr. Christopher R. Flowers delved into the meaning of MRD, discussing different ways that it may be tested for in patients with various types of cancer.
Image of man with brown hair.
January 11th 2025

A Breakdown of Trial Data that Led to the Subcutaneous Opdivo FDA Approval

Ryan Scott
Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.
Image of woman with blondish hair.
December 30th 2024

Empowering Patients With Cancer Through Clear Clinical Trial Communication

Darlene Dobkowski, MA
A clinical trial manager emphasizes the importance of a phased approach to educating patients about complex protocols and potential side effects.
Image of Jace.
December 24th 2024

Jace Yawnick of Jace Beats Cancer on the ‘Roller Coaster’ of Life in Remission

Alex Biese
After sharing his cancer story online, Jace Yawnick is in a state of technical remission after receiving a diagnosis of non-Hodgkin lymphoma at age 25.